Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) is one of today’s top gainers. The company’s shares are currently up -1.98% on the day to $14.72.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial.
So far today, approximately 194.72k shares of Aeglea BioTherapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 397.56k shares.
Aeglea BioTherapeutics, Inc. share prices have moved between a 52-week high of $39 and a 52-week low of $2.66. The stock has moved 8.6% over the past week.
To learn more about Aeglea BioTherapeutics, Inc., visit the company’s website at https://www.aeglea.com.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com